The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome

Rheumatology International

Volumn 32, Issue 12, 2012, Pages 3963-3967

  Kim, So Mi ^a   Park, Eugene ^a   Lee, Jung Hwa ^a   Lee, Sang Heon ^a   Kim, Hae Rim ^a  

^a Konkuk University School of Medicine   (South Korea)

Author keywords

Anti cyclic citrullinated peptide antibody; Arthritis; Rheumatoid factor; Sj gren syndrome

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SEROLOGY; SJOEGREN SYNDROME;

ARTHRALGIA; ARTHRITIS; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; SJOGREN'S SYNDROME;

EID: 84872276880     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2274-3     Document Type: Article

References (22)

1. Fox PC (2007) Autoimmune diseases and Sjogren's syndrome: An autoimmune exocrinopathy. Ann N Y Acad Sci 1098:15-21
2. Papiris SA, Tsonis IA, Moutsopoulos HM (2007) Sjogren's syndrome. Semin Respir Crit Care Med 28(4):459-471
3. Kassan SS, Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 164(12): 1275-1284
4. Ramos-Casals M, Font J (2005) Primary Sjogren's syndrome: Current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 44(11):1354-1367
5. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, Calvo-Alen J, Jimenez-Alonso J, Mico ML, Beltran J et al (2008) Primary Sjogren syndrome in Spain: Clinical, immunologic expression in patients. Medicine (Baltimore) 87(4):210-219
6. Manoussakis MN, Tzioufas AG, Pange PJ, Moutsopoulos HM (1986) Serological profiles in subgroups of patients with Sjogren's syndrome. Scand J Rheumatol Suppl 61:89-92
7. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101(1):273-281
8. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undiVerentiated arthritis: A prospective cohort study. Arthritis Rheum 50(3):709-715
9. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting Wve year radiographic damage. Ann Rheum Dis 62(2):120-126
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD et al (2010) Rheumatoid arthritis classification criteria: An American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 62(9):2569-2581
11. Sauerland U, Becker H, Seidel M, Schotte H, Willeke P, Schorat A, Schluter B, Domschke W, Gaubitz M (2005) Clinical utility of the anti-CCP assay: Experiences with 700 patients. Ann N Y Acad Sci 1050:314-318
12. Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62(9):870-874
13. Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, Dutoit V, Fauchais AL, Hachulla E, Flipo RM et al (2004) Evaluation of anti-citrullinated Wlaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63(4):415-419
14. Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, Caporali R (2008) Anti-cyclic citrullinated peptide antibodies in primary Sjogren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 10(3):R51
15. Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, Labarre C, Meyer O, Sibilia J, Mariette X (2005) Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 64(1):114-117
16. Barcelos F, Abreu I, Patto JV, Trindade H, Teixeira A (2009) Anticyclic citrullinated peptide antibodies and rheumatoid factor in Sjogren's syndrome. Acta Reumatol Port 34(4):608-612
17. Goeb V, Salle V, Duhaut P, Jouen F, Smail A, Ducroix JP, Tron F, Le Loet X, Vittecoq O (2007) Clinical significance of autoantibodies recognizing Sjogren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjogren's syndrome. Clin Exp Immunol 148(2):281-287
18. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS et al (2002) Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554-558
19. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62(5):427-430
20. Huo AP, Lin KC, Chou CT (2010) Predictive and prognostic value of antinuclear antibodies and rheumatoid factor in primary Sjogren's syndrome. Int J Rheum Dis 13(1):39-47
21. Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, Font J, Ingelmo M (2002) Primary Sjogren syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 81(4):270-280
22. Tomiak C, Dorner T (2006) Sjogren's syndrome-current aspects from a rheumatological point of view. Z Rheumatol 65:505-519